NCT01929356 Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia
| NCT ID | NCT01929356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Primary Ciliary Dyskinesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 29 participants |
| Start Date | 2020-06-30 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 29 participants in total. It began in 2020-06-30 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary ciliary dyskinesia (PCD) is a rare disease, caused by impairment of the motile cilia. Patients present with chronic upper and lower respiratory tract infections. The therapy is mainly supportive and based on that of cystic fibrosis. Chest physiotherapy is one of the cornerstones of the therapy, however the influence of chest physiotherapy on lung function (short term and long term) is not clear. For interpretation of longitudinal lung function data it is important to examine the short time effect of chest physiotherapy. We hypothesize that a session of chest physiotherapy improves lung function and that thus lung function tests must be performed in a standardized way.
Eligibility Criteria
Inclusion Criteria: * Primary ciliary dyskinesia * able to perform spirometry and MBW (\>6 years) Exclusion Criteria: * acute exacerbation
Contact & Investigator
Mieke Boon, MD
PRINCIPAL INVESTIGATOR
research fellow
Frequently Asked Questions
Who can join the NCT01929356 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 50 Years, studying Primary Ciliary Dyskinesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01929356 currently recruiting?
Yes, NCT01929356 is actively recruiting participants. Contact the research team at mieke.boon@uzleuven.be for enrollment information.
Where is the NCT01929356 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT01929356 clinical trial?
NCT01929356 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Mieke Boon, MD at research fellow. The trial plans to enroll 29 participants.